Skip to main content

Why are the billionaires always laughing?

Because they know the corporate media will never call bullshit on their bullshit.

Why are the billionaires laughing?

It’s easy to laugh when the corporate press treats you as a glorious success instead of the epitome of a broken social order. Billionaires laugh because they know the corporate media prefers to fawn over them rather than hold them to account.

Today, we ask you to support our nonprofit, independent journalism because we are not impressed by billionaires flying into space, their corporations despoiling our health and planet, or their vast fortunes safely concealed in tax havens across the globe. We are not laughing.

We are hard at work producing journalism for the common good. With our Fall Campaign underway, please support this mission today. We cannot do it without you.

Support Our Work -- Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Every donation—large or small—helps us bring you the news that matters.

A new report from Rep. Katie Porter (D-Calif.) takes pharmaceutical companies to task for their merger and acquisition activities. (Photo: Tom Williams/CQ-Roll Call, Inc.)

A new report from Rep. Katie Porter (D-Calif.) reveals how Big Pharma uses mergers and acquisitions to increase profits at the expense of Americans' healthcare. (Photo: Tom Williams/CQ-Roll Call, Inc.) 

New Report From Rep. Katie Porter Reveals How Big Pharma Pursues 'Killer Profits' at the Expense of Americans' Health

"It's time we reevaluate the standards for approving these mergers. It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies."

Brett Wilkins

Rep. Katie Porter on Friday published a damning report revealing the devastating effects of Big Pharma mergers and acquisitions on U.S. healthcare, and recommending steps Congress should take to enact "comprehensive, urgent reform" of an integral part of a broken healthcare system. 

"In 2018, the year that Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development."
—Report

The report, entitled Killer Profits: How Big Pharma Takeovers Destroy Innovation and Harm Patients, begins by noting that "in just 10 years, the number of large, international pharmaceutical companies decreased six-fold, from 60 to only 10."

While pharmaceutical executives often attempt to portray such consolidation as a means to increase operational efficiency, the report states that "digging a level deeper 'exposes a troubling industry-wide trend of billions of dollars of corporate resources going toward acquiring other pharmaceutical corporations with patent-protected blockbuster drugs instead of putting those resources toward' discovery of new drugs."

Merger and acquisition (M&A) deals are often executed to "boost stock prices," to "stop competitors," and to "acquire an innovative blockbuster drug with an enormous prospective revenue stream." 

"Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends," the report says, "all while swallowing smaller companies, thus making the marketplace far less competitive." 

The report calls M&As "just the tip of the iceberg of pharmaceutical companies' anti-competitive, profit-driven behaviors":

Pharmaceutical companies often claim that lowering the prices of prescription drugs in the United States would devastate innovation. Yet, as prices have skyrocketed over the last few decades, these same companies' investment in research and development have failed to match this same pace. Instead, they've dedicated more and more of their funds to enrich shareholders or to purchase other companies to eliminate competition.

"In 2018, the year that [former President] Donald Trump's tax giveaway to the wealthy went into effect, 12 of the biggest pharmaceutical companies spent more money on stock buybacks than on research and development," the report notes.

Some key findings from the report:

  • Big pharmaceutical companies are not responsible for most major breakthroughs in new drugs. Rather, innovation is driven in small firms, which are often spun off of taxpayer-funded academic research. These small labs are then purchased by giant firms after they've assumed the risk needed to develop a blockbuster drug;
  • Instead of producing lifesaving drugs for diseases with few or no cures, large pharmaceutical companies often focus on small, incremental changes to existing drugs in order to kill off generic threats to their government-granted monopoly patents; and
  • Mergers in the pharmaceutical industry have had an overall negative effect on innovation, taking what little competition existed in the industry and completely destroying it.

"Competition is central to capitalism," Porter said in a press release introducing the report. "As our report shows, Big Pharma has little incentive to invest in new, critically needed drugs. Instead, pharmaceutical giants are free to devote their resources to acquiring smaller companies that might otherwise force them to compete."

"Lives are on the line; it's clear the federal government needs to reform how it evaluates healthcare mergers and patent abuses," Porter added. 

To that end, Porter's report recommends the following actions:

"It's time we reevaluate the standards for approving these mergers," the report concludes. "It's time we pass legislation to lower drug prices. And it's time we rethink the structure of leadership at big pharmaceutical companies. Together, these strategies can help us bring more innovative, and critically needed, cures and treatments to market."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

New Whistleblower Sparks Calls to 'Crack Down on Facebook and All Big Tech Companies'

Hours after another ex-employee filed a formal complaint, reporting broke on internal documents that show the tech giant's failure to address concerns about content related to the 2020 U.S. election.

Jessica Corbett ·


'Catastrophic and Irreparable Harm' to Wolves Averted as Wisconsin Judge Cancels Hunt

"We are heartened by this rare instance of reason and democracy prevailing in state wolf policy," said one conservation expert.

Brett Wilkins ·


West Virginia Constituents Decry 'Immorality' of Joe Manchin

"West Virginia has been locked into an economy that forces workers into low-wage jobs with no hope for advancement, and after decades of this our hope is dwindling," said one West Virginian. "The cuts that Sen. Manchin has negotiated into the agenda hurt our state."

Julia Conley ·


'Texans Deserved Better Than This': Supreme Court Leaves Abortion Ban in Place

The nation's high court set a date to hear a pair of legal challenges to the "horrific" restrictions.

Jessica Corbett ·


'Like It Never Happened': Federal Judge Tosses Trump Attack on Clean Water Rule

Denying a Biden administration request to temporarily retain the rule, the judge reestablished "the careful balance of state and federal power to protect clean water that Congress intended when it wrote the Clean Water Act."

Brett Wilkins ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo